31 Jul 14
ProReveal Protein Detection Test with Process Validation Analytics Measures Effectiveness of Decontamination Process to Help Improve Patient Safety
Cambridge, UK: Scientific Digital Imaging's [AIM-SDI] Synoptics Health Division, a manufacturer of innovative digital imaging systems for healthcare applications, today introduced its next generation ProReveal with advanced process validation analytics software for detecting and analysing the amount of residual proteins on surgical instruments post-decontamination. The new ProReveal is designed to determine the effectiveness of the decontamination process, which will help hospitals to improve the cleanliness of their surgical instruments.
The ProReveal Test, a unique technology that quickly detects microgram levels of residual protein on re-processed surgical instruments, combines a touch screen ProReveal Viewer with new analytics software module and ProReveal fluorescence-based Protein Test Kit. The new software accurately analyses images and quantitative data generated by the ProReveal Viewer to determine where and how much protein remains on surgical instruments. Process criteria such as washing machine, tray number and position, detergent, operator and programme details can all be monitored to provide an overview of how effectively the decontamination processes are performing over time.
The addition of the powerful analytics software means the new ProReveal is now capable of being a precise diagnostic tool, allowing AEDs (Authorising Engineers Decontamination) in hospitals to validate and standardise every stage of their disinfection processes or manufacturers of decontamination equipment and detergents to optimise their products for maximum protein removal.
Paul Ellwood, CEO of Synoptics Health explained: "Removal of protein from surgical instruments is important not just because its presence is linked with causing hospital acquired infections but because instruments where the majority of the protein has been removed are considered to be safe for re-use. Our new ProReveal Test uses very sensitive fluorescence technology and unlike existing tests used in hospitals will tell you exactly how much protein is on your surgical instrument and where it is, and now how successful all aspects of your decontamination process are."
Paul added: "This is a totally different approach from current testing and is a significant break though because for the first time hospitals can accurately standardise and validate the decontamination process. Where this exciting technology is adopted by forward thinking AEDs in hospitals as a cleaning validation diagnostic, the new ProReveal will contribute to helping SSD staff provide safe, compliant reprocessed surgical instruments, thus reducing the numbers of post-surgical infections contracted via dirty instruments."
For Further Information Contact:
Jayne Arthur, Synbiosis, Beacon House, Nuffield Road, Cambridge, CB4 1TF, UK.
Tel: +44(0) 1223-727125 | Fax +44 (0) 1223-727101
Dr Sue Pearson, Director, International Science Writer, PO Box 170, Hitchin, Hertfordshire SG5 3GD, UK.
Web: www.internationalsciencewriter.com | Twitter: @isciencewriter
Note to Editors
With over 16 years’ experience, Synbiosis is a world-leading supplier of integrated imaging solutions for automatic counting and analysis of microbial colonies and zone measurement. The ProtoCOL, Protos and åCOLyte systems from Synbiosis are installed in food, pharmaceutical, environmental and research microbiology laboratories world-wide. Synbiosis uses established distribution channels to market its products internationally.
Synbiosis, founded in 1998 is a division of the Synoptics Group of the AIM quoted Scientific Digital Imaging Company based in Cambridge, UK. The Group’s other divisions, Syncroscopy and Syngene, specialise in digital imaging solutions for microscopy and molecular biology applications respectively. Synoptics currently employs 40 people in its UK and US subsidiary operation.